BPC's Comment on FDA's Generative AI-Enabled Medical Devices Discussion Paper
OVERVIEWThe Bipartisan Policy Center submitted formal comments on FDA's generative AI medical device framework, emphasizing the need for risk-based oversight that distinguishes between narrow-domain clinical AI and broad, general-purpose models used in healthcare. BPC's analysis highlights that FDA's regulatory approach must account for rapid AI evolution, the challenge of evaluating adaptive systems that change over time, and the tension between pre-market authorization requirements and post-market surveillance capabilities. The center advocates for flexible frameworks that can accommodate innovation while maintaining safety standards. Key recommendations include: establishing clear evidence standards for AI clinical validation, creating pathways for real-world evidence generation, ensuring transparency in AI training data and decision logic, and building provider and patient safeguards into regulatory requirements rather than treating them as secondary considerations. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.